Follow-up study on levetiracetam monotherapy in children with epilepsy / 中国当代儿科杂志
Chinese Journal of Contemporary Pediatrics
; (12): 711-714, 2008.
Article
en Zh
| WPRIM
| ID: wpr-317350
Biblioteca responsable:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and tolerability of levetiracetam (LEV) in the treatment of epilepsy as a monotherapy in children.</p><p><b>METHODS</b>Thirty-two children with epilepsy (age ranged from 8 months to 12 years) and who had received LEV monotherapy were investigated by a self-controlled and open-label research. LEV was administered at a dose of 10 mg/kg.d, and increased by 10 mg/kg.d per week till to the target dose (20-40 mg/kg.d), with a mean dose of 35 mg/kg.d.</p><p><b>RESULTS</b>Thirty-one patients were followed up for more than three months. Twenty-five patients (80.6%) had at least 50% reduction in seizures, 22 cases (70.9%) became seizure-free, and LEV therapy was discontinued in 5 patients (16.1%) due to either an inadequate seizure control or aggravated seizures. The therapy-related adverse events included mood and behavioral changes (6/31, 19.4%), asthenia (2/31, 6.5%), somnolence (2/31, 6.5%), and skin rashes (1/31, 3.2%). The adverse effects were spontaneously disappeared or disappeared after reducing the LEV dose.</p><p><b>CONCLUSIONS</b>LEV monotherapy is effective and safe for the control of partial and generalized tonic-clonic seizures in children with epilepsy. LEV appears to be a promising anti-epileptic drug for monotherapy in children with epilepsy.</p>
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Piracetam
/
Estudios de Seguimiento
/
Usos Terapéuticos
/
Quimioterapia
/
Epilepsia
/
Anticonvulsivantes
Tipo de estudio:
Observational_studies
/
Prognostic_studies
Límite:
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Idioma:
Zh
Revista:
Chinese Journal of Contemporary Pediatrics
Año:
2008
Tipo del documento:
Article